ArticleAntimicrobial agents and chemotherapy1997
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.
Article in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Surfactin and Capric Acid Affect the Posaconazole Susceptibility ofInternational journal of molecular sciences · 2023Article
- Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi.PloS one · 2016Article
- Advances in synthetic approach to and antifungal activity of triazoles.Beilstein journal of organic chemistry · 2011Article
- In search of the holy grail of antifungal therapy.Transactions of the American Clinical and Climatological Association · 2008Review
- In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Antimicrobial agents and chemotherapy · 2006Article
- Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist.Pharmacy world & science : PWS · 2005Review
- Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.Antimicrobial agents and chemotherapy · 2001Article
- In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.Antimicrobial agents and chemotherapy · 2000Article
- In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens.Antimicrobial agents and chemotherapy · 2000Article
- Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.Antimicrobial agents and chemotherapy · 2000Article
- Treatment of murine fusariosis with SCH 56592.Antimicrobial agents and chemotherapy · 1999Article
- Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.Clinical microbiology reviews · 1999Review
- Current and emerging azole antifungal agents.Clinical microbiology reviews · 1999Review
- Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.Journal of clinical microbiology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro activity of Schering 56592, a new azole drug, was compared with those of fluconazole and itraconazole against 103 isolates of Candida comprising 10 different species. Schering 56592 was more active than itraconazole and fluconazole, and it was active against many fluconazole-resistant isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.